Test the safety and efficacy of RC16 for cancer treatment.
The lead compound, RC16, displayed strong cytotoxic activity and was chosen for further study. The IC50 of RC16 for normal cells was tenfold higher than for tumor cells. RC16 exhibited significant antitumor effects in vivo in several cancer models by both intravenous and oral administration routes. RC16 strongly improved the survival in the metastatic model. In addition to its activity as an antitumor drug, amphiphilic amines (RCn) are useful for encapsulating traditional chemotherapies and thereby enhancing their efficacy and reducing their side effects. RC16 has been evaluated for its ability to complex other bioactive molecules. The amphiphilic character of RC16 triggered a spontaneous molecular self-assembling in water with formation of micelles allowing complexation of Doxorubicin, Etoposide and Paclitaxel. These micelles significantly improved the in vitro antitumor activity of these drugs as the enhancement of their aqueous solubility also improved their biologic availability. Thus, RC16 may be useful as a novel cancer treatment.
Potential Applications: Potential applications not yet defined for this project
Your request to become a member has been submitted.